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Preface
In an effort to respond to the need for thoughtful and
objective use of healthcare services in the delivery of
high-quality care; the American College of Radiology
(ACR) and the American College of Cardiology Founda-
tion (ACCF) have taken on the important process of jointly
determining the appropriate use of cardiovascular imaging
modalities for specific important clinical scenarios in pa-
tients with heart failure (HF). The ultimate objective of an
Appropriate Utilization of Imaging (AUI) document is to
improve patient care and health outcomes. The ACR,
ACCF, and the collaborators in this document believe that
careful balancing of a broad range of clinical experiences and
available evidence-based information will help guide a more
effective, efficient and equitable allocation of healthcare
resources.
The publication of the AUI in HF document reflects the
first collaboration between the ACR and ACCF. This effort
is aimed at critically and systematically creating, reviewing,
and categorizing clinical situations where physicians order
or use imaging tests for patients with suspected, incom-
pletely characterized, or known HF. This document is based
on our current understanding of the technical capabilities
and potential patient benefits of the various imaging mo-
dalities examined. The clinical scenarios do not directly
correspond to the Ninth Revision of the International
Classification of Diseases system. Rather, the scenarios
presented represent common clinical scenarios seen in
contemporary practice, but do not include every conceivable
clinical situation. Thus, some patients seen in clinical
practice are not represented in this document or have
additional extenuating features compared with the clinical
scenarios presented. Of course, both the ACR and ACCF
support personalized patient care, emphasizing utilization of
diagnostic and therapeutic approaches to meet the specificneeds of each patient. These AUI criteria are intended to
provide guidance for patients and clinicians, but are not
intended to diminish the acknowledged difficulty or uncer-
tainty of clinical decision making and cannot act as substi-
tutes for sound clinical judgment and practice experience.
This document provides a framework for decisions regard-
ing judicious utilization of imaging in the management of
patients with suspected, incompletely characterized or
known HF seen in clinical practice.
In developing the AUI for HF document, the joint
Radiology and Cardiology writing panel implemented a
process that evaluated the technical abilities of the multiple
imaging modalities being rated and the evidence for each
modality with respect to the clinical indication and the
imaging parameters important to each clinical indication.
Therefore, the method for development of this AUI for
HF document highlights the best aspects of both the
current ACR and ACCF processes. A multidisciplinary
rating panel comprised imagers, cardiovascular clinicians,
general practitioners, and outcomes experts assessed
whether performing an imaging procedure for each clin-
ical indication was appropriate, maybe appropriate, or
rarely appropriate, based on available evidence at the time
of their review.
Michael Bettmann, MD
Co-Chair, AUI Oversight Committee
Michael J. Wolk, MD
Co-Chair, AUI Oversight Committee
Introduction
Clinicians, payers, and patients are interested in the specific
benefits offered by imaging to both the diagnosis and
clinical management of disease conditions. This document
addresses the appropriate use of imaging procedures in
patients with HF.
Other appropriate-use publications from the ACCF and
their collaborating organizations reflect an ongoing effort to
critically and systematically create, review, and categorize
the appropriate utilization of imaging by modality. The
ACR Appropriateness Criteria documents critically ex-
amine and categorize appropriateness of multiple imag-
ing modalities used in the diagnosis and management of
over 170 specific clinical conditions and their common
variants. This document follows the methods described in
greater detail in a joint publication by ACCF and ACR
that itself combines the individual methodology publica-
tions of the ACCF and the ACR (1). The intent of the
current document is to examine the benefits of imaging
by explicitly considering 2 complex questions: 1) Is any
imaging at all justified for a given clinical scenario? and 2)
If yes, which imaging modality or modalities are most
likely to provide meaningful incremental information?
p
g
s
p
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effort.
Heart Failure Overview
Prevalence
HF represents a rapidly growing epidemic (2–6). Approx-
imately 5.8 million patients in the United States currently
suffer from HF, and over 670,000 of them are newly
diagnosed with HF each year (7).
Clinical Significance
More deaths result from HF causing sudden cardiac death
than from all forms of cancer combined; the 5-year mortal-
ity after a diagnosis of HF is approximately 50% (7).
Economic Impact
Annual medical expenditures related to HF in the United
States exceed $39.2 billion (7).
Although medical imaging has been reported as one of
the fastest growing segments of Medicare expenditures,
with cardiovascular imaging accounting for nearly one-third
of those costs (8), recent data demonstrate declining rates of
use, potentially reflecting the ongoing efforts to encourage
appropriate use (9).
Basic Therapeutic Options
In general, the ACCF/American Heart Association (AHA)
Heart Failure Guidelines provide in-depth information on
the management and prevention of HF (10). The main
objectives of imaging for HF evaluation revolve primarily
around understanding both cardiac structure and function,
and, secondarily, in determining the underlying etiology, so
that proven medical and invasive therapies may be targeted
to appropriate patients. Therefore, the clinical indications
presented in this report focus on these management prin-
ciples in patients with suspected, incompletely character-
ized, or known HF.
Methods for Establishing Appropriate Use of
Imaging in HF
The methods are described in detail in a recent related joint
publication (1). A summary is given in the following text. In
brief, this process combines evidence-based medicine,
guidelines, and practice experience by engaging a technical
panel in a modified Delphi exercise (11).
Need for Appropriate Utilization of Imaging in HF
There is heightened interest regarding the appropriateness
of imaging in HF patients due to:
• The increasing prevalence of HF, especially in the
elderly;
• Dramatic developments in advanced imaging modali-
ties with overlapping capabilities;• Advancements in surgical and percutaneous therapies
for conditions causing HF;
• Improvements in medical therapy for HF; and
• The high costs of in-hospital and out-patient HF
management.
Importantly, utilization of imaging categorized as rarely
appropriate may generate unwarranted costs to the health-
care system and cause harm due to unnecessary follow-up
testing or treatments to HF patients, whereas appropriate
utilization of imaging procedures should improve manage-
ment and clinical outcomes in HF patients, justifying their
use.
Definition of Appropriateness
The definition of an “appropriate” imaging test, according
to the joint methods of ACR and ACCF, is based on the
definition of appropriateness in “AQA Principles for Appro-
riateness Criteria” (12a). (The principles are a subset of the
eneral “AQA Parameters for Selecting Measures for Phy-
ician Performance” [12b] and are not to be viewed inde-
endently of that document.)
The concept of appropriateness, as applied to health care,
balances risk and benefit of a treatment, test, or procedure in
the context of available resources for an individual patient
with specific characteristics. Appropriateness criteria should
provide guidance to supplement the clinician’s judgment as
to whether a patient is a reasonable candidate for the given
treatment, test or procedure (12a, para. 2).
This definition highlights the central intent of achieving of
the greatest yield of clinically valuable diagnostic informa-
tion from imaging with the least negative impact on the
patient.
Clinical Scenario and Indication Identification by
Writing Group
The writing panel for this HF project comprised practicing
Radiology and Cardiology representatives from the relevant
professional societies. The writing panel initially recognized
key areas of HF clinical care from which general clinical
scenarios leading to the consideration of imaging use were
identified (see Figure 1). The identified key clinical entry
points for HF-directed imaging included:
• Newly Suspected or Potential HF
• HF Associated With Myocardial Infarction (MI)
• HF Assessment for Consideration of Revascularization
• Consideration of and Follow-Up for Device Therapy (Im-
plantable Cardioverter-Defibrillator [ICD] or Cardiac Re-
synchronization Therapy [CRT])
• Repeat Evaluation of HF
These clinical scenarios are intended to be broad and
representative of the most common patient situations in HF
for which assistance from diagnostic imaging is considered.
Information gained from imaging may contribute to the
original diagnosis but is not sufficient by itself to establish a HF
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through an evaluation of the patient for a constellation of signs
and symptoms consistent with HF. Once a diagnosis is made
or a high likelihood established, imaging may be used in the
evaluation and management of HF.
Early in the preparation of this document, the writing
panel concluded that nonischemic etiologies of HF repre-
sent an important subset of patients; however, addressing
this clinical scenario would significantly expand the scope of
this document. Although a few of the indications for
suspected or potential HF may be the result of nonischemic
etiologies, these patients were generally not addressed in
this document. The intent is to include nonischemic etiol-
ogies in a subsequent document. The development of the
relationships between the 5 remaining clinical scenarios
highlights the complexity of the decision-making process
for clinical management and use of imaging in patients with
suspected, incompletely characterized, or known HF. The
document is intended to address the use of imaging within
the 5 described broad clinical scenarios. Entry into a given
scenario may be based on history, signs, symptoms or other
factors, such as incidental diagnosis of low left ventricular
ejection fraction (LVEF).
Guidance for Clinical Scenarios and Indications
This document includes 5 clinical scenarios. For each of
the 5 general clinical scenarios, the writing panel identi-
fied specific clinical indications, emphasizing that each
indication represents the specific “point-of-order” for an
imaging study. These clinical indications are meant to
capture the salient features seen at the time of patient
Newly Suspected or Potential 
Heart Failure
Evaluati
Viability
Before R
Consideration of and Follow-Up 
for Device Therapy (ICD or CRT) 
Heart Failure Associated With MI
Known Heart Failure Without 
Established Etiology
Heart Failure Assessment for 
Consideration of 
Revascularization
Repeat Evaluation of Heart Failure 
Figure 1. Entry Points Into Clinical Imaging Scenariosencounter before a procedure is ordered. Some of theimportant features represented in the indications of
patients with HF included:
a) The clinical presentation (e.g., dyspnea, exertional
fatigue, chest pain or angina/ischemic equivalent,
murmur, crackles, edema),
b) Severity of HF (New York Heart Association
[NYHA] functional class I, II, III, or IV),
c) Prior determination of underlying etiology (e.g., isch-
emic/nonischemic etiology of HF),
d) Exacerbating conditions (e.g., dietary indiscretion,
new angina/ischemic equivalent).
The writing panel recognized that for routine patient
care, symptom status, underlying etiology of HF, and the
level of medical therapy are factors that play critical roles in
decision making but may not be completely represented in
a clinical scenario. The reader should note that the clinical
indications focus on imaging modalities in HF, rather than
biomarkers or other clinical management procedures.
Once the indications were drafted, reviewers from collabo-
rating medical specialty and subspecialty groups, including
radiology, cardiology and general medical societies, along with
other stakeholders, were given the opportunity to review and
provide feedback regarding the appropriate use document for
HF, and this was incorporated into the document.
The following was written to clarify the different sections
for the rating panel, as well as the general user of this
document: The procession of clinical scenarios was chosen
to reflect the clinical work-up of a patient and to highlight
the diagnostic imaging query at a given clinical indication.
Evaluation for Ischemic 
Etiology 
Baseline Evaluation of 
Structure and Function 
See Clinical 
Scenario #1 
See Clinical 
Scenario #2 
mic Burden 
cularization 
Evaluation for 
Nonischemic Etiology of 
Heart Failure
See Clinical 
Scenario #4 
Not Covered (See 
Comments) 
See Clinical 
Scenario #3 
See Clinical 
Scenario #5 on of 
/Ische
evasThe first clinical scenario reflects the de novo evaluation of
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step: the evaluation of ischemic versus nonischemic etiology
in patients presenting for evaluation of HF symptoms. The
extent and severity of ischemia is then followed by consid-
eration of a viability assessment (i.e., Scenario #3), largely in
the setting of extensive LV dysfunction, where revascular-
ization is under consideration. These 2 distinctions between
Scenarios #2 and #3 will help raters to make the distinction
between these 2 sections. In some cases, the assessment of
ischemic burden (i.e., Scenario #2) may be combined with
or circumvent the need for a viability assessment (i.e.,
Scenario #3), where the former case of severe ischemia may
be the principal driver for considering revascularization.
The next scenario, #4, focuses on the application of
imaging for decisions regarding ICD and CRT. The final
scenario addresses the role of serial imaging in the
evaluation of HF patients. Raters should take care to
evaluate the role of imaging in each of these scenarios
separately and to rely to as great an extent as possible on
the evidence presented here that relates to the evaluation
of patients with HF symptoms.
The Rating Panel and Its Function
In order to reduce bias in the rating process, the rating panel
comprised physicians with varying perspectives on imaging
in HF and not solely of technical experts (e.g., cardiac
imagers). Overrepresentation of technical experts in a rating
panel might create a perceived preference for imaging in
general or for a specific imaging modality when other
clinical alternatives (including no testing strategies) may be
more commonly employed.
Stakeholders in HF care had the opportunity to partici-
pate in the appropriate-use HF assessment process by
submitting nominees for the rating panel from their orga-
nizations through a call-for-nominations released in May
2009. From this list of nominees, the oversight committee
and writing panel selected rating panel members to ensure
that a balance with respect to expertise was achieved.
In addition, care was taken to provide objective, peer-
reviewed, unbiased information, including a broad range of
key references, to the rating panel members. Recognizing
variability in many patient factors, local practice patterns,
and a lack of data on use of imaging across clinical scenarios
and indications, the rating panel members were asked to
independently rate the appropriateness of using each imag-
ing modality for the general scenario and specific indication
based on the available evidence. Specifically, each rating
panel member was asked to go through the following steps
in developing their individual rating:
1. Review all the clinical scenarios/indications for HF
imaging.
2. Review the descriptions of all imaging modalities—
both safety table and table of imaging parameters
addressing the capabilities of each imaging modality.3. Review the literature review for HF (summary state-
ments, key reference evidence tables, and parameter-
based evidence lists).
4. Rate each imaging modality for each indication by
level of appropriateness first (Appropriate/Maybe ap-
propriate/Rarely appropriate).
5. Provide numeric scores (described in next section) for
modalities in each level based on amount and quality
of evidence and additional factors such as safety and
cost.
The rating panel used a 1 to 9 scale to rate the appro-
priateness of an imaging procedure for the specific indica-
tion/scenario (see the Rating Appropriate Use section).
Rating panel members initially voted independently on the
appropriateness of each imaging procedure for all the
clinical indications. The results were then tabulated and
returned to the rating panel members in the form of their
individual scores along with the de-identified scores from
the other members. A mandatory in-person meeting of the
rating panel was then held to review and propose indication
revisions to the writing panel. The in-person meeting
included non-rating representatives of the writing panel and
oversight committee, who provided guidance relative to
procedural and operational issues and ensured continuity
throughout the process. The oversight committee representa-
tive also served as an unbiased moderator to the rating panel
and facilitated optimal group dynamics during the process. The
oversight committee moderator was free of significant relation-
ships with industry and was unbiased relative to the topics
under consideration. The revised narrative and indications then
underwent a second round of independent rating. For indica-
tions with significant dispersion of scores, a conference call and
third round of rating occurred.
Relationships With Industry and Other Entities
The American College of Cardiology Foundation, Ameri-
can College of Radiology, and partnering organizations
rigorously avoid any actual, perceived, or potential conflicts
of interest that might arise as a result of an outside
relationship or personal interest of a member of the tech-
nical panel. Specifically, all panelists are asked to provide
disclosure statements of all relationships that might be
perceived as real or potential conflicts of interest. These
statements were reviewed by the Appropriate Use Criteria
Task Force, discussed with all members of the technical
panel at the face-to-face meeting, and updated and reviewed
as necessary. A table of disclosures by all participants is
presented in the Appendix.
Rating Appropriate Use
Based on available evidence, the rating panel members
assigned a rating to each imaging procedure for a specific
clinical scenario/indication on a continuous scale from 1 to
9. Final ratings are reported as categories. The category and
complete definitions used in this document were modified
by the AUI Oversight group after the final ratings were
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produced by ACR and ACCF. The new terminology is
similar to the UCLA RAND Appropriateness Method
labels (11) used by the rating panel (appropriate, uncertain,
and inappropriate) but clarifies that appropriateness is a
continuum as discussed in the remainder of the document
and discussed with the rating panel during the meeting.
Appropriate Score 7 to 9:
An appropriate option for management of patients in this
population due to benefits generally outweighing risks;
effective option for individual care plans although not always
necessary depending on physician judgment and patient
specific preferences (i.e., procedure is generally acceptable
and is generally reasonable for the indication).
Maybe Appropriate Score 4 to 6:
At times an appropriate option for management of
patients in this population due to variable evidence or
agreement regarding the benefits/risks ratio, potential benefit
based on practice experience in the absence of evidence, and/or
variability in the population; effectiveness for individual care
must be determined by a patient’s physician in consultation
with the patient based on additional clinical variables and
judgment along with patient preferences (i.e., procedure may
be acceptable and may be reasonable for the indication).
The “maybe appropriate” category indicates that the
rating panel agreed that: 1) there was insufficient evidence
whether the imaging procedure was appropriate or not; or
2) the available evidence was equivocal or conflicting; or
3) additional factors beyond those described must be con-
sidered. A “maybe appropriate” rating is more likely with
procedures using new technology or protocols for which the
evidence is limited and additional research is required. All
raters recognize that a rating in the “maybe appropriate”
category does not invalidate the use of specific imaging on a
case-by-case basis when the best interests of an individual
patient are being considered by the caring physician. The
ACCF and the ACR recommend that a “maybe appropri-
ate” category not be used as justification for the nonpayment
of imaging services.
Rarely Appropriate Score 1 to 3:
Rarely an appropriate option for management of patients
in this population due to the lack of a clear benefit/risk
advantage; rarely an effective option for individual care
plans; exceptions should have documentation of the clinical
reasons for proceeding with this care option (i.e., procedure
is not generally acceptable and is not generally reasonable
for the indication).
The following specific assumptions were conveyed to the
rating panel members:
• All imaging is performed in accredited laboratories using
approved/certified imaging equipment (12–16).
• All interpreting physicians are qualified to supervise
the imaging procedure and report the findings on the
resulting images.• All imaging will be performed according to peer-
reviewed published medical literature.
• In the clinical scenarios/indications, no unusual exten-
uating circumstances (e.g., clinically unstable, inability
to undergo the imaging modality considered, resusci-
tation status, patient unwilling to continue medical
care or revascularization), exist or have been specifi-
cally noted.
• Prior diagnostic imaging may have been performed by
the time of the clinical presentation. The panel should
rate the appropriateness of imaging in the clinical
scenario independent of the appropriateness of prior
imaging.
• The potential drawbacks of the imaging procedures
include those presented in the Imaging Procedures and
Safety Information table (Appendix B) of the ACCF/
ACR methodology document and those associated
with poor test performance (1).
• While specific patient groups (e.g., end-stage renal
disease, advanced age), which are not well represented
in the literature, are not presented in the current
clinical scenarios/indications, the writing group recog-
nizes that decisions about imaging in such patients are
frequently required.
• All patients are receiving standard care, including
guideline-based risk factor modification for primary or
secondary prevention in cardiovascular patients, and
standard HF care unless specifically noted.
• Cost may be a consideration, in particular as it relates
to the use of lower cost, noninvasive versus more
costly, invasive procedures. However, clinical benefits
should always be considered first, and costs should be
considered in relationship to these benefits. Use of a
lower-cost procedure, though less expensive at a given
moment in time, may ultimately be more costly due to
subsequent expenses. A procedure may initially be
more costly, but it may be better able to address the
clinical questions at hand.
Identification and Description of
Cardiovascular Imaging Modalities
The cardiovascular imaging modalities considered in this
report included the following: echocardiography (echo),
cardiovascular magnetic resonance (CMR), single-photon
emission computed tomography (SPECT), positron emis-
sion tomography (PET), cardiovascular computed tomog-
raphy (CCT; CCT includes CT angiography and calcium
scoring), and conventional diagnostic cardiac catheteriza-
tion (catheterization includes coronary angiography, left
ventriculography, left heart catheterization). All of these
modalities represent multiple capabilities that are selectively
used alone or in combination during an episode of care or
serially throughout a patient’s life in order to provide general
insights into a clinical condition or to assess specific issues
pertaining to the individual patient. In fact, the specific
performance of the same imaging modality may vary con-
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with the same general disease. This variability in the
description of the imaging technology applied is also re-
flected in the literature. Thus, for the sake of establishing
(by evidence-based analysis) the appropriateness of imaging
it is essential to delineate the key clinical parameters for
imaging to address on an indication-by-indication basis to
be able to assess the relative roles of the various modalities.
That is the intent of the “Imaging Parameters Evidence”
online supplement.
To ensure that the rating panel and users of the criteria
can apply the indications to practice, the specific parameters
included in clinical evaluations and levels-of-evidence vali-
dation for use are provided in the following tables. The
expectation is that the modalities and imaging techniques
used are not experimental, but rather that they represent a
reasonable and usual high quality of imaging, as available in
general practice.
CLINICAL SCENARIO #1
Initial Evaluation of Cardiac Structure and
Function for Newly Suspected or Potential
Heart Failure
Clinical Rationale
The cardinal presenting symptoms of HF are dyspnea and
fatigue, resulting from variable combinations of fluid reten-
tion (manifested as pulmonary congestion and/or peripheral
edema) and exercise intolerance (10). Symptoms of HF also
may be accompanied by signs such as murmur, abnormal
jugular venous pressure, crackles, other signs of volume
overload, or edema.
The clinical syndrome of HF is common and can be
caused by any disorder impairing the ability of the ventricles
to contract, relax, fill, or empty during the cardiac cycle (10).
Although HF may be due to abnormalities of the myocar-
dium, valves, or pericardium, the majority of HF patients
are symptomatic from LV myocardial functional abnormal-
ities, which may be seen in settings ranging from markedly
reduced LVEF with/without severe LV dilation (predomi-
nantly, systolic dysfunction) (10,17) to preserved LVEF
with normal LV size (predominantly, diastolic dysfunction)
(10,18). In many cases, systolic and diastolic myocardial
dysfunctions coexist. Coronary artery disease (CAD), hy-
pertension, valvular disease, and dilated cardiomyopathy are
the causes of HF in a substantial proportion of patients,
with aging being an important contributor to diastolic
dysfunction (10,19,20).
In patients presenting with signs and symptoms that raise
suspicion of HF, assessment of LV systolic and diastolic
function is important and can be performed with a variety of
imaging techniques. The same holds true for patients who
are at risk for HF, such as patients after acute MI, those
with hypertension and left ventricular (LV) hypertrophy,
those who are exposed to potentially cardiotoxic chemother-apeutic agents, and first-degree relatives of those with an
inherited cardiomyopathy.
Imaging Rationale
Although a complete history and physical examination are
the first steps in evaluating the etiology of newly suspected
HF, or factors predisposing to HF, identification of struc-
tural abnormalities leading to HF generally requires imag-
ing of the cardiac chambers and great vessels (10,21).
Imaging may be used in new-onset HF to determine
whether abnormalities of the myocardium, valves, or peri-
cardium are present, which chambers are involved, and
whether secondary pulmonary arterial hypertension is pres-
ent. Imaging is also often very useful in such patients for
early prognostication. For example, LVEF after MI remains
a strong predictor of risk, with lower LVEF associated with
worse outcome (22–25).
Use of imaging allows the following fundamental ques-
tions to be addressed in patients with newly suspected or
potential HF:
1. Is LV structure normal or abnormal?
2. Is LVEF preserved or reduced?
3. Is ventricular relaxation normal? and
4. Are there other structural abnormalities accounting for
the clinical presentation?
Evaluation, however, is not limited to the LV.
For this clinical scenario, the following imaging param-
eters are most relevant:
Anatomy
1. Chamber anatomy abnormalities (geometry/dimension/
wall thickness)
2. Valve structural abnormalities
3. Congenital abnormalities
4. Pericardial abnormalities (including calcification/fluid/
thickness/constriction)
Function
1. Global ventricular systolic dysfunction (including re-
duced ejection fraction and stroke volume)
2. Global ventricular diastolic dysfunction (including al-
tered [reduced or increased] early ventricular filling)
3. Valve dysfunction (stenosis/regurgitation/other abnor-
malities)
Myocardial Status
1. Regional ventricular systolic dysfunction (including wall
thickening)
Literature Review
Summary Statement
The literature review does not support routine use of stress
imaging with echo, CMR, SPECT, or PET for initial
evaluation of HF symptoms.
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The strongest recommendations in favor of imaging of
patients with newly suspected HF are with echocardiogra-
phy to include 2-dimensional transthoracic ultrasound and
Doppler (10). Among its most attractive attributes are its
widespread availability, lack of ionizing radiation, and the
application of imaging in real time. Assessments of cardiac
structure and function can be made accurately to guide therapy.
Multicenter studies have demonstrated the value of various
echocardiographic measures of cardiac structure and function
as indicators of subclinical HF and risk for subsequent HF
events (27–31). Additionally, assessment of LV systolic func-
tion using echo in patients with suspected HF improved the
disease identification by general practitioners as well as the
application of appropriate medical care (32). Resting echocar-
diography has also been shown to identify patients with HF
with preserved systolic function and abnormal diastolic func-
tion (33,34) and to predict subsequent poor outcomes (35–37).
CMR
Studies over the last decade support the use of CMR for this
cohort of patients, as noted in a recently published expert
consensus statement (37a). Although LV volume and EF
measurements are at least as accurate as those obtained with
echo (38), myocardial perfusion, viability, and fibrosis imaging
can assist in identification of etiology and assess prognosis (39).
V mass quantitation by CMR predicts future risk in patients
ith HF (40). A key strength of CMR is the high resolution
f the anatomy of all aspects of the heart and surrounding
tructures (41). This has led to recommendations for use in
atients with known or suspected complex congenital heart
isease (42). The accuracy of CMR and its utility in the initial
ssessment of valve function appear substantial, although some
uestions are not yet entirely answered.
PECT
PECT is not primarily used to determine LV systolic
lobal and regional function; unless these parameters are
uantified from the resultant images during myocardial
erfusion assessment (see Scenario #2) (43,44).
adionuclide Ventriculography
imilar to CMR and echo, radionuclide ventriculography
RNV) is an additional alternative that may be applied to
he evaluation of cardiac function (45). RNV is a planar
echnique, and it may be particularly useful for the assess-
ent of LV volumes in patients with significant resting wall
otion abnormalities or distorted geometry. Due to the
uantitative methods employed in this technique, it has
igh reproducibility (46). Serial RNV measurements of LV
olumes have been reported to track the efficacy of a variety
f therapeutic interventions for patients with HF (47–49).
RNV is a technique that is less commonly performed today
than in years past and is not routinely used in patients with
adult congenital heart disease.PET
There are relatively few data to support the use of PET as
an initial test, but reports do note the utility of peak stress
LVEF measurements (50).
CCT
CCT can provide accurate assessment of cardiac structure
and function. This technique has high anatomic resolution
for the heart and surrounding structures, including the
coronary arteries. One current limitation is the loss in
accuracy with high heart rate values. An advantage of CCT
over echo may be its ability to characterize the myocardium,
but studies have yet to demonstrate the importance of this
factor. Currently, limited reports are available with CCT in
patients with suspected HF.
Catheterization
The invasive assessment of hemodynamics and valvular and
ventricular function by catheterization with left ventriculogra-
phy is considered the traditional reference standard (51). How-
ever the invasive nature of the test, radiation exposure, and
necessary geometric assumptions in calculations have gradually
reduced reliance on this approach as an initial diagnostic test for
LV function, especially in subjects who are deemed low risk.
Guidelines
The relevant guideline recommendations for this clinical
scenario are:
Initial clinical assessment of patients presenting with HF:
ACC/AHA Heart Failure Guidelines (10)
CLASS I
1. 2-Dimensional echo with Doppler should be performed during
initial evaluation of patients presenting with HF to assess LVEF,
LV size, LV wall thickness, and valve function. Radionuclide left
ventriculography can also be performed to assess LVEF and
volumes. (Level of Evidence: C)
ACC/AHA ST-Segment Elevation MI (STEMI)
Guidelines (51a)
CLASS IIa
1. Echocardiography is reasonable in patients with ST-segment
elevation MI to re-evaluate ventricular function during recovery
when results are used to guide therapy. (Level of Evidence: C)
Assessment of patients at risk for developing HF:
ACC/AHA Heart Failure Guidelines (10)
CLASS I
1. Healthcare providers should perform a noninvasive evaluation of
LV function (i.e., LVEF) in patients with a strong family history of
cardiomyopathy or in those receiving cardiotoxic interventions.
(Level of Evidence: C)
ACC/AHA STEMI Guidelines (51a)
CLASS IIa
1. Echocardiography is reasonable in patients with STEMI to re-
evaluate ventricular function during recovery when results are
used to guide therapy. (Level of Evidence: C)
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INDICATION
Rest Only Rest  Stress
CCT CathEcho RNV SPECT PET CMR Echo SPECT PET CMR
Newly Suspected or Potential Heart Failure
1. Symptoms of heart failure
● Shortness of breath OR
● Decreased exercise tolerance OR
● Symptoms of fluid retention AND
Findings of heart failure
● Abnormal chest radiograph (e.g.,
enlarged silhouette, pulmonary
venous congestion) OR
● Abnormal biomarker(s)
(e.g., BNP, pro-BNP) OR
Signs of heart failure
● Evidence of impaired perfusion
OR
● Evidence of volume overload
A A M R A R R R R M R
2. Malignancy
● Current or planned cardiotoxic
therapy AND
● No prior imaging evaluation
A A R R A R R R R R R
3. Familial or genetic dilated
cardiomyopathy in first-degree
relative
A M R R A R R R R R R
4. Known adult congenital heart
disease
A M R R A R R R R M M
5. Acute myocardial infarction
● Evaluation of LV function during
initial hospitalization
A M M R A M M R R R ABNP  B-type natriuretic peptide.CLINICAL SCENARIO #2
Evaluation for Ischemic Etiology
Clinical Rationale
The increasing prevalence of chronic ischemic heart disease,
reflecting the significant accomplishment of improved sur-
vival among patients after acute coronary events (e.g., acute
myocardial infarction), combined with the general aging of
the population (2–6), has resulted in an increasing preva-
lence of HF. Based on patient enrollment in therapeutic
randomized trials, approximately two-thirds of patients
have an ischemic etiology of their HF symptoms (52). Thus,
identification of an underlying ischemic etiology is central to
clinical management strategies for HF.
Imaging Rationale
It is assumed that patients in this clinical scenario have
evidence for HF with a reasonable suspicion of cardiac
ischemia, whether by prior cardiac events, risk factors, or
current symptoms and signs. Cardiovascular imaging can
help evaluate the severity of CAD and associated myocardial
ischemia. It can also aid identification of the extent of either
infarcted or hibernating myocardium. Although the primary
rationale for quantitating the extent and severity of myocar-
dial ischemia is to guide important clinical decisions regard-ing medical therapy versus revascularization, there are but a
few small clinical trials and observational reports supporting
this approach (53,54). Although there is limited random-
ized trial evidence available regarding the benefits of ther-
apeutic intervention (55), the assessment of myocardial
ischemia is valuable due to evidence of a higher relative
hazard for CAD events in patients with severe ischemia
treated medically (54). Evaluation of coronary anatomy
and pathology currently requires the consideration of
modalities that may utilize a contrast agent, so renal
functional status must be considered. A specific classifi-
cation scheme for renal function in this setting has not
yet been widely accepted, despite the use of chronic
kidney disease class, and therefore, institution-specific
classifications should be used.
As noted in the Preface, this scenario focuses on defining
whether or not ischemia is the etiology for HF symptoms
and should be seen as preceding a viability assessment that
may be performed if needed to further guide therapeutic
decision making.
For this clinical scenario, the following imaging param-
eters are most relevant:
Anatomy
1. Coronary artery abnormalities (including atherosclerotic
disease, anomalies)
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1. Global ventricular systolic dysfunction (including re-
duced ejection fraction and stroke volume)
2. Valve dysfunction (stenosis/regurgitation/other abnormalities)
Myocardial Status
1. Fibrosis/scarring (transmural extent/mural distribution/
pattern)
2. Regional ventricular systolic dysfunction (including wall
thickening)
3. Inducible ischemia—decreased perfusion
4. Inducible ischemia—decreased contraction
Literature Review
Summary Statement
Available evidence regarding the optimal method for eval-
uation of patients with classical angina, ischemic equivalent
pain, dyspnea-equivalent angina, or extensive proven or
suspected silent myocardial ischemia and HF is character-
ized by observational studies with various imaging modali-
ties that demonstrate diagnostic performance and additional
prognostic series (56). The recently published STITCH
(Surgical Treatment for Ischemic Heart Failure) trial eval-
uating medical versus surgical revascularization (57) pro-
vides evidence regarding the benefit of revascularization
with regard to cardiovascular events.
In patients with increasing renal dysfunction, modalities
that use iodinated or gadolinium-based contrast agents pose
increased risk and should be avoided when suitable alterna-
tives exist.
Literature Review—By Imaging Test
Echo
Stress echo has been shown to identify both resting and
post-stress systolic wall motion abnormalities in many
observational studies (58–60). In many of these observa-
tional studies, ischemia was defined as new/worsening wall
motion abnormality (WMA) or a biphasic response (defined
as WMA augmentation at low-dose with deterioration at
high-dose dobutamine stress echocardiography). These
findings have been related to clinical outcomes.
CMR
Perfusion CMR studies have been performed in patients
without systolic dysfunction for the identification of CAD,
but have not been extensively studied in HF patients. CMR
has been studied in small series used to evaluate wall motion
with stress in patients with HF (61). CMR with high
resolution has more often been used to detect fibrosis, a
technique that, in observational studies, has identified isch-
emic versus nonischemic cardiomyopathy in HF patients.
Recent preliminary reports have linked fibrosis with clinical
outcome (62,63). wSPECT
SPECT has been studied extensively in HF patients to
determine both ischemia and prognosis. Moreover, obser-
vational evidence supports the concept that patients referred
to stress myocardial perfusion imaging (MPI) with dyspnea
are high risk (56). A benefit to the use of SPECT imaging
is the addition of rest and post-stress gated LVEF and wall
motion information in addition to MPI measurements,
including both visual (qualitative) and quantitative measure-
ments (65). For patients referred for evaluation of symptoms
suggestive of HF, the results of stress MPI have been
applied to differentiate ischemic from nonischemic cardio-
myopathy. Significant and extensive angiographic CAD oc-
curs frequently in patients with high-risk stress MPI findings.
Finally, reports on the use of stress MPI have focused on the
utility of ischemia as a marker of downstream improvement in
LV function. In the CHRISTMAS (Carvedilol Hibernation
Reversible Ischaemia Trial, Marker of Success) trial, a total of
305 patients with HF were enrolled and randomized to
carvedilol versus placebo (66). There was a gradient relation-
ship, with the number of ischemic segments and improvement
in LV function noted at approximately 6 months of follow-up.
In a recent prospective, controlled clinical trial, 201 patients
following index hospitalization for HF underwent stress MPI
(67). This cohort included a broad range of LVEF measure-
ments, including 36% of patients with preserved systolic
function. When the stress MPI (i.e., summed stress score 3,
ndicating at least mildly abnormal) results were compared
ith invasive coronary angiography in 75 patients, the sensi-
ivity and specificity of stress MPI for detection of any
ignificant CAD stenosis were 82% and 57%, respectively. For
xtensive CAD in the proximal left anterior descending
LAD) or left main, or multivessel CAD, the sensitivity and
pecificity were 96% and 56%, respectively.
ET
ata regarding the use of PET in this setting are largely
erived from studies that include patients undergoing evalua-
ion of myocardial viability. An advantage of the use of stress
PI with PET is its improved accuracy for the detection of
evere, multivessel CAD, which may appear as balanced
eduction and normal SPECT findings. Moreover, PET
arkers of absolute peak stress LVEF measurements and
yocardial perfusion reserve may improve detection of patients
ith CAD (50,68). Some small-series studies have noted the
dvantage of quantifying the extent of myocardial scarring and
nsulin resistance as important prognostic findings from PET
69). Finally, altered glucose metabolism and myocardial efficiency
ave also been studied in small series and may offer an added
eans to identify high-risk patients with HF using PET (70,71).
NV
s noted in the previous text, gated SPECT or PET
easures of LV volumes provide similar information and
ith concomitant performance of rest and stress myocardial
t
c
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cated for ascertaining ischemic etiologies for HF.
CCT
CCT has been examined in some preliminary studies of
patients with HF and has been shown to have a high
negative predictive value in confirming the absence of CAD
(72–74). In a small study, electron beam CT showed
promise in identifying CAD in HF patients when compared
with catheterization (40,72).
Catheterization
Cardiac catheterization has shown obstructive CAD in
patients with HF with and without angina/ischemic equiv-
alent in observational studies (76–78) and is considered a
central study by the ACCF/AHA guidelines. Additionally,
cardiac catheterization was used solely as the entry criteria
for determination of obstructive CAD in patients enrolled
in the STITCH trial and other trials of coronary revascu-
larization versus medical therapy.
Guidelines
The relevant guideline recommendations for this clinical
scenario are:
ACC/AHA Heart Failure Guidelines (10)
Patient With Angina/Ischemic Equivalent Syndrome/In this table, all patients have known HF, are suspected of having ischemia, and are assumed to be re
ompromise limiting myocardial blood flow with evenCLASS I
1. Coronary arteriography should be performed in patients present-
ing with HF who have angina or significant ischemia unless the
patient is not eligible for revascularization of any kind. (Level of
Evidence B)
CLASS IIa
1. Coronary arteriography is reasonable for patients presenting with
HF who have angina/ischemic equivalent that may or may not be
of cardiac origin who have not had evaluation of their coronary
anatomy and who have no contraindications to coronary revas-
cularization. (Level of Evidence: C)
CLASS IIb
1. Noninvasive imaging may be considered to define the likelihood of
CAD in patients with HF and LV dysfunction. (Level of Evidence: C)
Patient Without Angina/Ischemic Equivalent Syndrome/
Angina
CLASS IIa
1. Coronary arteriography is reasonable for patients presenting with
HF who have known or suspected CAD, but who do not have
angina, unless the patient is not eligible for revascularization of
any kind. (Level of Evidence: C)
2. Noninvasive imaging to detect myocardial ischemia and viability
is reasonable in patients presenting with HF who have known
CAD and no angina, unless the patient is not eligible for
revascularization of any kind (20). (Level of Evidence: B)
CLASS IIb
1. Noninvasive imaging may be considered to define the likelihood
of CAD in patients with HF and LV dysfunction. (Level of
Angina Evidence: C)
Table 2. Evaluation for Ischemic Etiology
INDICATION
Rest Only Rest  Stress
CCT CathEcho RNV SPECT PET CMR Echo SPECT PET CMR
6. Angina/ischemic equivalent
syndrome
M R R M M A A A A A A
7. WITHOUT angina/ischemic
equivalent syndrome
M R R M M A A A A M Avascularization candidates.CLINICAL SCENARIO #3
Viability Evaluation (After Ischemic Etiology
Determined) Known to Be Amenable to
Revascularization With or Without
Clinical Angina
Clinical Rationale
A subpopulation of patients with known CAD and chronic
LV dysfunction is thought to have potential reversibility of
LV dysfunction if successfully revascularized by coronary
artery bypass graft (CABG) or percutaneous coronary in-
tervention (PCI). The underlying pathophysiologic sub-
strate has been termed hibernating myocardium (79), and is
hought to result from significant coronary arterial luminalminimal demand, such that the myocardium “down-
regulates” contractility, gradually or through repetitive stun-
ning, to match the diminished blood flow as a possible
compensatory or adaptive mechanism. The result is a state
of chronic LV dysfunction, which often may manifest
clinically as HF with or without anginal symptoms.
The clinical scenario in which identification of such a patient is
important is: 1) history of CAD amenable to revascularization by
CABG or PCI; 2) chronic regional and/or global LV dysfunction;
and 3) symptoms of HF and/or angina.
Imaging Rationale
The goal of imaging is to define whether dysfunctional
myocardial regions are the result of prior infarction, current
hibernating state, or a combination. The important impli-
cation of making such a distinction is that if sufficient
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present, the patient may benefit clinically from revascular-
ization. If the regional dysfunction is predominantly due to
infarction, then the clinical implication is that revascular-
ization would confer no benefit, and thus the risks of
revascularization outweigh the potential benefits. A prop-
erty of dysfunctional but viable myocardium in the setting of
chronic ischemic heart disease is “contractile reserve,” that
is, the ability to increase contractility for a brief period of
time during an inotropic stimulus. Unfortunately, its assess-
ment is limited in the setting of ischemic HF. The presence
of clinical angina may indicate the presence of viable
myocardium; however, this is often clinically weighed
against the degree of LV dysfunction. Scenarios based on
the presence of angina (or angina/ischemic equivalent), the
level of LV dysfunction, and wall thinning are used to help
identify situations in which differing imaging tests for
viability may add value.
For this clinical scenario, the following imaging param-
eters are most relevant:
Anatomy
1. Chamber anatomy abnormalities (geometry/dimension/
wall thickness)
2. Coronary artery abnormalities (including atherosclerotic
disease)
Function
1. Global ventricular systolic dysfunction (including re-
duced ejection fraction and stroke volume)
2. Valve dysfunction (stenosis/regurgitation/other abnormalities)
Myocardial Status
1. Fibrosis/scarring (transmural extent/mural distribution/
pattern)
2. Regional ventricular systolic dysfunction (including wall
thickening)
3. Inducible ischemia—decreased perfusion
4. Inducible ischemia—decreased contraction
5. Hibernating state—positive contractile reserve
6. Hibernating state—anaerobic metabolism/glucose utilization
7. Hibernating state—minimal scarring
Literature Review
Summary Statement
Evidence for the use of viability imaging in patients with
impaired LV dysfunction is currently available from several
meta-analyses of observational studies that demonstrate recov-
ery of function and clinical improvement in patients undergo-
ing revascularization with evidence of viable myocardium
(80,81). The recently published small substudy of the
STITCH trial did not find improved outcomes in a nonran-
domized cohort of patients undergoing viability testing.Echo
Contractile reserve with echo can be imaged using dobut-
amine echo, and manifests in the dysfunctional region of
interest as an increase in wall thickening and motion during
low doses of dobutamine, with a subsequent impairment of
contractility at higher doses, a finding termed “biphasic
response.” This technique has been shown in observational
studies to identify myocardial segments with higher likeli-
hood of functional recovery after coronary revascularization
in patients with moderately reduced LVEF (median 31%)
(76). Contractile reserve may be limited in patients with
thinned LV walls (82).
CMR
CMR identification of hibernating myocardium and poten-
tial reversibility of LV dysfunction is based on the use of late
enhancement gadolinium imaging, in combination with
information on regional function available with cine CMR
techniques. Observational studies have demonstrated that
“viability,” defined by the relative absence of scarring, resulted
in improvement in myocardial function following coronary
revascularization in patients with preserved (83) and severely
depressed LV function (84). Post-infarction risk stratification
with pharmacological stress CMR data is also available (85).
Dobutamine stress CMR is also useful for diagnosing CAD
(86). Additionally, CMR has been show to demonstrate
subendocardial infarction with a greater sensitivity than
SPECT in small observational series (87,88).
SPECT
Studies with SPECT tracers involving biopsies of regional
myocardium in patients undergoing CABG have demon-
strated that the degree of uptake of the tracers (by quanti-
tative analysis) correlates directly with the magnitude of
regional myocyte tissue viability on biopsies, thus validating
the use of this technique in this scenario. Observational
studies of SPECT imaging in patients with HF have
identified worse prognosis in patients without viable myo-
cardium (89). In a large systematic review of 24 published
reports, the accuracy of SPECT, PET, and echo for
prognostication was similar (80).
PET
In 2 randomized trials, a strategy of fluorodeoxyglucose
(FDG)-PET–directed revascularization has been compared
with standard care for decisions regarding revascularization
(PARR 1 and PARR 2 [Positron Emission Tomography
and Recovery Following Revascularization 1 and 2] trials)
(91,92). These studies demonstrated that patients with
viability who underwent revascularization had evidence of
improved myocardial function. In addition, when com-
pared with SPECT, FDG-PET was able to identify
viable myocardium with a higher sensitivity (93). Al-
though PET is reported to have greater sensitivity, the
clinical relative value in comparison to SPECT with
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clearly been demonstrated (94).
RNV
As noted earlier in the text, gated SPECT or PET measures of
LV volumes provide similar information, and with concomitant
performance of rest and stress MPI, the use of RNV is generally
not indicated for the assessment of myocardial viability.
CCT
Preliminary studies suggest that CCT imaging may provide
similar information as CMR using contrast enhancement
with regard to delineation of etiology of LV dysfunction and
to identify areas of regional infarction, in combination with
readily available information on regional function (95,96).
However, this technique has not as yet been widely used for
this purpose, and validation studies are more preliminary in
nature compared with the robust literature on all of the
other noninvasive imaging modalities.
Catheterization
There is limited initial evidence on the use of left ventricu-
lography for the determination of viability and response to
revascularization. With the advent of newer noninvasiveNYHA functional class III to IV symptoms demonstrate aGuidelines
The relevant guideline recommendations for this clinical
scenario are:
ACCF/AHA UA/NSTEMI (97a)
CLASS I
1. Percutaneous coronary intervention or CABG for patients with 1-
or 2-vessel CAD without significant proximal LAD CAD, but with
a large area of viable myocardium and high-risk criteria on
noninvasive testing. (Level of Evidence: B)
CLASS IIa
1. Use of PCI or CABG for patients with 1-or 2-vessel CAD without
significant proximal LAD disease, but with a moderate area of
viable myocardium and demonstrable ischemia on noninvasive
testing. (Level of Evidence: B)
CLASS III
1. Use of PCI or CABG for patients with 1-or 2-vessel CAD without
significant proximal LAD disease who have mild symptoms that
are unlikely to be due to myocardial ischemia, or who have not
received an adequate trial of medical therapy and have only:
a. A small area of viable myocardium; or
b. Have no demonstrable ischemia on noninvasive testing.techniques, this has not been subsequently studied. (Level of Evidence: C)
Table 3. Viability Evaluation (After Ischemic Etiology Determined) Known to Be Amenable to
Revascularization With or Without Clinical Angina
INDICATION
Rest Only Rest  Stress
CCT CathEcho RNV
SPECT Rest/
Redistribution PET CMR Echo SPECT PET CMR
8. Severely reduced ventricular
function (EF 30)
M R A A A A A A A M R
9. Moderately reduced ventricular
function (EF 30%–39%)
M R M A A A A M A M R
10. Mild ventricular function
(EF 40%–49%)
M R M M A A A A A M RCLINICAL SCENARIO #4
Consideration and Follow-Up for
Implantable Cardioverter-Defibrillator (ICD)/
Cardiac Resynchronization Therapy (CRT)
Clinical Rationale
The LV dilation and dysfunction associated with significant
HF frequently lead to ventricular tachyarrhythmias, the
most common rhythms causing sudden cardiac death in HF
patients (10,97). Sudden cardiac death in HF can be
decreased by the use of an ICD (98).
HF with severely depressed LV function is frequently
accompanied by impaired electromechanical coupling, lead-
ing to prolonged ventricular conduction (usually left bundle
branch block) with regional mechanical delays (98). Ap-
proximately one-third of HF patients with low LVEF andQRS duration 0.12 s, the primary marker for dyssynchro-
nous ventricular contraction (10,98). The mechanical con-
sequences of LV dyssynchrony include:
1. Accentuated LV dysfunction with increased metabolic
demand;
2. Suboptimal ventricular filling;
3. Functional mitral regurgitation;
4. Paradoxical interventricular septal motion; and
5. Adverse remodeling with increased LV dilation
(10,98–103).
For HF patients, dyssynchronous LV contraction is also
associated with increases in cardiac mortality (10,104–106).
In persistently symptomatic patients, CRT alone results
in significant improvements in:
1. Quality of life;
2. Functional class;
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4. LVEF (10,98,107).
CRT also reduces repeat hospitalizations and mortality
due to NYHA functional class III to IV HF when compared
with standard medical therapy (107–109).
Imaging Rationale
Use of an ICD requires placement of standard intracavitary
leads into the right atrium and right ventricle for proper
monitoring and pulse delivery.
LV dyssynchrony, and its adverse effects, can be reduced by
synchronous electromechanical activation of the LV, using a
biventricular pacing device for CRT (10,98,110,111). CRT re-
quires advancement of an LV lead retrograde through the
coronary sinus into a tributary overlying the LV free wall, as
well as placement of standard right atrial and right ventricular
leads.
Currently, the major reasons for imaging in the setting of
consideration for ICD or CRT device implantation are, first,
demonstration of LVEF35%, and secondly, delineation of the
mount and the location of ventricular asynchrony. Both have a
ajor impact on outcomes following device placement.
For this clinical scenario, the following imaging param-
ters are most relevant:
natomy
. Cardiac vein variations (for CRT implantation)
unction
. Global ventricular systolic dysfunction (including re-
duced ejection fraction)
. Valve dysfunction (stenosis/regurgitation/other abnormalities
yocardial Status
. Inflammation
. Fibrosis/scarring (transmural extent/mural distribution/
pattern)
. Regional ventricular systolic dysfunction (including wall
thickening)
. Myocardial wall mechanics (including strain and syn-
chrony analysis)
iscellaneous
. Thrombus—atrial
. Thrombus—ventricular
Literature Review
ICD
Cardiovascular imaging for consideration of ICD implan-
tation is mainly based on the evaluation of LV systolic
function. In the SCD-HeFT (Sudden Cardiac Death in
Heart Failure Trial), the distribution of LVEF values
measured by echo, contrast left ventriculography, and ra-
dionuclide angiography differed, but clinical outcomes did
not (112). Repeat imaging for ICD implantation may bedone to determine whether a course of therapy (either
revascularization or medical) has improved the ventricular
function or whether the patient still meets LVEF criteria.
Therefore, again the goals of imaging are dependent on LV
systolic function as described in the preceding text.
CRT
Cardiovascular imaging for consideration of CRT implan-
tation also is mainly based on the evaluation of LV systolic
function. The majority of the large randomized CRT
studies have used echo to evaluate LV systolic function
before and after implantation. Other imaging modalities
have been used to evaluate LV systolic function, but with
limited studies in patients undergoing CRT. Identification
of cardiac vein anatomy for CRT implantation has been
shown with CCT and, in some smaller studies, with CMR,
and invasive cardiac catheterization. CCT does provide the
means to assess LV dyssynchrony and pulmonary vein anatomy
with a single study, as, in theory, does CMR. Despite several
observational studies that evaluated different imaging modali-
ties for identifying potential predictors of clinical response to
CRT, however, available randomized trial data do not dem-
onstrate improved outcomes. Up to 30% of carefully selected
HF candidates do not show benefit from CRT and possibly
progressive worsening despite CRT (113,114). It should be
noted that the literature for CRT use and the concomitant use
of imaging modalities to direct therapy is one of the fastest
evolving fields. This report captures the best available literature
for existing standard technologies; however, several newer
techniques and technologies may prove important in the
upcoming years. Finally, several available guideline recommen-
dations are provided, and they currently only require an EF
evaluation and dyssynchrony based on the QRS duration.
Post-Implantation—Follow-Up Imaging
Studies with repeat imaging after ICD implantation for clin-
ically stable patients without a change in status have not been
conducted. For patients with clinical deterioration or change in
arrhythmia status, evaluation of a change in ventricular func-
tion or in CAD/ischemia may be warranted based on guideline
recommendations for standard care of symptomatic HF.
In patients with improved HF class and LV systolic
function following CRT implantation, routine clinical im-
aging has not been studied.
Literature Review—By Imaging Test
Echo
Echo has been studied in the assessment of LVEF before
ICD implantation such as in the SCD-HeFT (42). Several
observational studies have evaluated the value of echo in
identifying and predicting response to CRT (115–118)
Tissue Doppler imaging is superior to strain rate imaging
and post-systolic shortening on the prediction of reverse
remodeling in both ischemic and nonischemic HF after
CRT (119,120). A large randomized trial using echo-based
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not show a clinical benefit (121).
In patients with failure to respond to CRT or with
worsening clinical status, studies with echo have been used
to maximize atrioventricular intervals and programming of
the CRT device while monitoring LV systolic function and
mitral regurgitation (122,123). Echo has also been shown to
identify patients with dyssynchrony who are missed by
electrocardiography criteria alone (124,125).
CMR
CMR has been demonstrated to reliably image LV systolic
function, but with limited studies to date in patients being
considered for ICD placement. CMR has been shown to
identify fibrosis that may lead to future ventricular tachy-
cardia/ventricular fibrillation in patients with (126) and
those without an ICD (127,128). CMR has also shown the
ability to demonstrate LV thrombus and pulmonary vein anatomy
and relationships.
Repeat imaging with CMR is not routinely performed in
patients with an intracardiac device due to both safety
concerns and limitations in the ability to acquire diagnostic
images.
Observational studies with CMR in patients under con-
sideration for CRT have shown that patients with areas of
fibrosis, specifically near potential lead placement areas, do
not demonstrate clinical improvement with CRT (129).
One study found CMR to be more sensitive for fibrosis than
SPECT in prospective CRT patients.
RNV and Gated SPECT
RNV for LVEF is highly reproducible when compared with
echo and has been used as an inclusion test for randomized
trials demonstrating the benefit of ICD implantation
(46,112). Rest and post-stress gated LVEF measurements
are also routinely applied and are highly reproducible as part
of a CAD evaluation (65). Various SPECT measures of
dyssynchrony in patients undergoing CRT have been stud-
ied, with some studies correlating with echocardiographic
measures. Observational studies have evaluated SPECT
measures of dyssynchrony in patients undergoing CRT to
determine patients that will respond to the therapy (130).
From a recent report in 44 patients, phase analysis of gated
SPECT was accurate in predicting acute change in LV
synchrony and patient outcome following CRT (131,132).PET
Data for the use of PET in patient being considered for
ICD implantation are limited. Initial PET studies have
identified potential areas of fibrosis in patients with CRT,
and attempted to differentiate responders from nonre-
sponders to CRT.
CCT
CCT has had promising in initial studies evaluating LV
systolic function. Recent reports have noted the utility of
CCT for ICD placement, including venous imaging before
ICD, quantitation of dyssynchrony, and EF assessment.
Guidelines
The relevant guideline recommendations for this clinical
scenario are:
ACC/AHA Heart Failure Guidelines (10)
CLASS I
ICD
1. Primary prevention of sudden cardiac death in HF are for patients
with:
a. Nonischemic dilated cardiomyopathy or ischemic heart dis-
ease >40 days post-MI;
b. LVEF <35%;
c. NYHA functional class II or III despite optimal medical ther-
apy; and
d. A reasonable expectation of survival with a good functional
status for more than 1 year.
CLASS I
ICD
1. Secondary prevention in order to prolong survival in HF patients
with:
a. Current or prior HF symptoms;
b. Reduced LVEF; and
c. A history of cardiac arrest, ventricular fibrillation, or hemodynami-
cally destabilizing ventricular tachycardia.
CLASS I
1. CRT (with or without ICD) use in patients with HF are:
a. LVEF <35%;
b. Sinus rhythm;
c. NYHA functional class III or ambulatory class IV symptoms
despite optimal medical therapy; and
d. Cardiac dyssynchrony (defined as QRS duration >0.12 s),
CRT (with or without combined ICD).
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Cardiac Resynchronization Therapy (CRT)
INDICATION
Rest Only Rest  Stress
CCT CathEcho RNV SPECT PET CMR Echo SPECT PET CMR
Implantable Cardioverter-Defibrillator Therapy
11. Evaluation determine patient candidacy (133)
● Meets published clinical standards for
device eligibility
● Candidacy requires assessment of ejection
fraction and/or other structural information
A A M R A R R R R M R
12. Routine follow-up after placement
● No deterioration in clinical status AND
● No change in arrhythmia status
R R R R R R R R R R R
13. Follow-up after placement
● Change in arrhythmia status
● Appropriate ICD discharge (e.g., VT/VF)
A R M R R R R R R M R
14. Follow-up after placement
● Change in arrhythmia status
● Inappropriate ICD discharge (e.g. rapid AFib)
A R M R R R R R R R R
Cardiac Resynchronization Device Therapy
15. Initial evaluation to determine patient
candidacy (133)
● Meets published clinical standards for
device eligibility
● Candidacy requires assessment of ejection
fraction
A A M R A R R R R M R
16. Procedure planning: considerations
● Patient meets all published clinical
standards for device
● Evaluation of myocardial fibrosis/scarring,
coronary vein variations, and intra-cavitary
thrombus (for dyssynchrony evaluation)
A R R R A R R R R A R
17. Follow-up early (6 months) after
implantation
● No improvement in symptoms OR
● No improvement functional capacity
A M M R R R R R R M R
18. Follow-up late (6 months) after
implantation
● Improved symptoms (i.e., from class III, IV
to class I, II) OR
● Improved functional capacity
M R R R R R R R R R RAFib  atrial fibrillation; VF  ventricular fibrillation; VT  ventricular tachycardia.CLINICAL SCENARIO #5
Repeat Evaluation of HF
Clinical Rationale
Optimal medical therapy permits HF patients to now lead
longer and more functional lives. Regardless of the etiology,
however, HF is a chronic process often characterized by
gradual clinical deterioration.
Imaging Rationale
Noninvasive imaging may be used to assess prognosis or to
optimize treatment in patients with known and previously-
evaluated HF. Many of the previously discussed imaging
parameters are used to re-assess patients.
For this clinical scenario, the following imaging param-
eters are most relevant:Anatomy
1. Coronary artery abnormalities (including atherosclerotic
disease)
Function
1. Global ventricular systolic dysfunction (including re-
duced ejection fraction)
2. Valve dysfunction (stenosis/regurgitation/other abnormalities)
Myocardial Status
1. Fibrosis/scarring (transmural extent/mural distribution/
pattern)
2. Regional ventricular systolic dysfunction (including wall
thickening)
3. Inducible ischemia—decreased perfusion
4. Inducible ischemia—decreased contraction
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6. Hibernating state—anaerobic metabolism/glucose utilization
7. Hibernating state—resting dysfunction/minimal scarring
Literature Review
Summary Statement
Although a common clinical situation, little published literature
exists regarding repeat imaging and evaluation of patients with
HF. The majority of literature is associated with re-evaluation for
consideration of implantable defibrillator therapy or efficacy of
resynchronization therapy. Both of these clinical situations and
their relevant literature are reviewed in Scenario #4.
Regarding stable patients without a change in clinical status, a
few studies have demonstrated that radionuclide imaging, echo,
and CMR can reliably demonstrate a change in LVEF after
medical therapy (134–138). However, there were no studies
found that identified a clinical benefit in routine serial imaging in
patients without a change in clinical status. Measures of rest and
stress LVEF measures with gated SPECT and RNV have beennization devices, and the use of imaging in longitudinalGated SPECT/RNV
Measures of rest and stress LVEF measures with gated
SPECT and RNV have been shown to be highly reproduc-
ible (64,139). Accordingly, numerous reports have evaluated
the role of serial measurements of LV volumes to track the
efficacy of a variety of therapeutic interventions for patients
with HF (47–49,140,141).
Guidelines
The relevant guideline recommendations for this clinical
scenario are:
ACC/AHA Heart Failure Guidelines (10)
CLASS IIa
1. Repeat measurement of EF and the severity of structural remod-
eling can be useful to provide information in patients with HF who
have had a change in clinical status or who have experienced or
recovered from a clinical event or received treatment that might
have had a significant effect on cardiac function. (Level ofshown to be highly reproducible (64,139). Evidence: C)
Table 5. Repeat Evaluation of HF
INDICATION
Rest Only Rest  Stress
CCT CathEcho RNV SPECT PET CMR Echo SPECT PET CMR
19 New angina or ischemic equivalent syndrome A M M M M A A M M M A
20. New or increasing HF symptoms (e.g.,
shortness of breath or exertional dyspnea)
AND
Adherent to medical therapy
A M M R M A A M M M M
21. No new symptoms AND
No other change in clinical status
Less than 1 year since prior imaging
R R R R R R R R R R R
22. No new symptoms AND
No other change in clinical status
Greater than or equal to 1 year since prior
imaging
M R R R R R R R R R RDiscussion
The current document represents the first joint effort by the
American College of Radiology and American College of
Cardiology Foundation to address appropriate utilization of
cardiovascular imaging in HF patients. As such, the docu-
ment represents the efforts of both professional societies,
countless individuals, and the groups’ hope is that it will
help optimize the care of patients with HF. Because HF is
a complex medical syndrome consisting of several possible
underlying etiologies and/or exacerbating conditions, the
writing group attempted to provide a framework for con-
sidering the clinical indications, Figure 1. This framework
includes indications aimed at evaluating structure and func-
tion, underlying ischemic etiology, viability for revascular-
ization decisions, determination and the need for evaluation
of patients being considered for defibrillators and resynchro-follow-up of patients. Even with this robust set of scenarios,
the writing group and the rating panel recognized that all
the possible indications are not covered in this first docu-
ment; for example, the evaluation of nonischemic underly-
ing etiologies for individuals presenting with new-onset HF
represents an important area not covered. Nevertheless, the
process of reviewing the available literature, presenting
common clinical scenarios, and having a wide spectrum of
clinical experts in both cardiology and radiology rate the
indications for HF imaging has provided some important
lessons for the clinical community. The lessons from the
literature review and conclusions from the rating panel
will be presented as general concepts and by clinical
indications.
The writing group and rating panel acknowledge that
there are many diagnostic procedures used to evaluate
patients with HF. The writing group and rating panel did
not rate resting electrocardiogram or chest x-rays because
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general history and physical examinations when appropriate.
The procedures that were considered included both rest and
rest/stress tests where possible, for echo, radionuclide im-
aging (including RNV, SPECT, PET), and CMR. Addi-
tionally imaging of cardiac structures and coronary angiog-
raphy with cardiac CT and invasive cardiac catheterization
were considered as well. In total, this represented 11
possible tests for several clinical indications. This required a
detailed review of both the possible technical capabilities
and the clinical data reported for these modalities. Finally,
the writing group also used available documents from both
ACR and ACCF to determine the safety data for these
procedures. The online appendices (see Literature Review
and Imaging Parameters Evidence) provide these technical
capability and safety data and should provide an important
reference for future reviews and for individuals who want to
review a specific reference.
Clinical Indications
Review of the clinical indications provides some important
themes and lessons. For patients undergoing initial evalua-
tion for potential or suspected HF, the rating panel found
no role in general for routine use of stress cardiovascular
imaging, cardiac CT, or invasive angiography. Both echo
and CMR were felt to be procedures that would provide
clinically meaningful information. The rating panel felt that
if the only information needed is EF, then RNV may also be
a possibly useful test. However, for more routine evaluation
for comprehensive cardiac structure and function, including
in patients with familial cardiomyopathy, congenital heart
disease patients, or post-MI patients, both echo and CMR
were felt to be more useful imaging modalities. The panel
also noted that ventricular function evaluation (i.e., ven-
triculography) might also be performed at time of coronary
arteriography in acute MI or suspected ischemia.
Once HF has been clinically diagnosed, and the cardiac
structure and function has been determined, the rating panel
preferred stress testing with any of the available modalities,
or angiography with CT, or invasive cardiac catheterization.
In patients with HF and angina, invasive cardiac catheter-
ization and angiography was felt to be appropriate, if the
patient was otherwise a candidate for revascularization.
With regard to viability, the writing group attempted to
provide recommendation stratified by 3 general categories of
ventricular dysfunction, severe (EF 30%), moderate (EF
30% to 39%), and mild (EF 40% to 49%). It should be noted
that patients with LVEF  35% or less are candidates for
defibrillators, and viability testing was considered indepen-
dent of determination for need for devices therapy. The
literature and the rating panel opinions suggested many of
the modalities were sufficient for determining viabilityacross a spectrum of patients. Resting CMR and PET were
felt to be appropriate and useful in the patients with severe
ventricular dysfunction, along with the possibility of stress
echo or SPECT scan.
For patients being considered for devices therapy, both
ICD and CRT, many studies are underway to maximize
device function with the use of imaging. However, the
available evidence does not as yet support criteria for device
therapy beyond LVEF. Therefore, echo and CMR testing
were felt to be useful in patient selection. Additionally,
CMR and cardiac CT were rated as appropriate for device
planning, often to help map the coronary vein anatomy for
CRT implantation. CMR was felt to be useful for identi-
fication of myocardial fibrosis and possible thrombus. The
rating panel felt that most of these patients did not need a
stress evaluation or invasive cardiac catheterization. Finally,
the rating panel felt it was appropriate to re-evaluate LV
function for patients who had a change in clinical status
including ICD discharge or who had their device activated,
but thought the indication for routine follow-up EF testing
was rarely appropriate, with the possible exception of
echocardiography, which was rated as maybe appropriate.
These concepts were carried for the longitudinal assess-
ment of patients. For the patients with changing symptoms
and presentation with either worsening HF symptoms
(where a change in structure or function was suspected), the
rating panel rated the indication similar to the initial
evaluation with consideration for testing. For patients with
changing symptoms and additional concerns for ischemia,
again the rating panel thought stress testing was reasonable.
For patients with HF and no change in symptoms, the
rating panel in general felt testing was rarely appropriate.
These ratings will hopefully provide guidance at the time of
test consideration, especially in patients with HF who are
seen in multiple locations within the healthcare system.
The partnership between the ACR and ACCF should be
seen as a model for review of diagnostic imaging and should
be incorporated into future efforts. We acknowledge the
great variation in the clinical presentation of patients with
HF, and therefore provide these appropriate use criteria as
recommendation to be used in conjunction with sound
clinical judgment. We believe the implementation of these
criteria in decision support tools with population or practice
review will augment clinical care and hopefully lead to high
quality and efficient care. Finally, we also recognize that
many aspects of clinical care in patients with HF is rapidly
evolving with increasing evidence for effective therapies and
diagnostic tests, and therefore anticipate that this document
will need to be updated in a timely fashion. In the interim,
we believe these ratings will be important useful guidance at
the point of care for patients with HF.
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